MyFinsight
Home
Blog
About
Proceeds from
underwritten registered...
$145,659K
Proceeds from exercise of
stock option awards
$1,696K
(1246.03%↑ Y/Y)
Proceeds from issuance of
common stock under the...
$998K
(63.07%↑ Y/Y)
Net cash provided by
financing activities
$147,436K
(15.19%↑ Y/Y)
Canceled cashflow
$917K
Net increase in
cash, cash...
$3,877K
(-94.28%↓ Y/Y)
Canceled cashflow
$143,559K
Payment of offering
costs-Underwriting Agreement
$864K
Payment of debt issuance
costs
$53K
Maturities of marketable
securities
$34,000K
something is missing
$20,000K
Stock-based compensation
expense
$9,187K
(42.15%↑ Y/Y)
Accrued expenses and
other liabilities
$3,976K
(515.46%↑ Y/Y)
Non-cash lease expense
$843K
(-45.37%↓ Y/Y)
Depreciation expense
$391K
(-70.67%↓ Y/Y)
Other assets
-$193K
(-972.22%↓ Y/Y)
Amortization of debt discount
and debt issuance...
$127K
Amortization of premiums on
marketable securities, net
-$7K
Net cash used in
investing activities
-$128,506K
(-18470.23%↓ Y/Y)
Net cash used in
operating activities
-$15,053K
(74.73%↑ Y/Y)
Canceled cashflow
$34,000K
Canceled cashflow
$34,724K
Purchases of marketable
securities
$162,399K
Net loss
-$44,727K
(32.71%↑ Y/Y)
Purchases of property and
equipment
$107K
(-84.54%↓ Y/Y)
Prepaid expenses and
other current assets
$1,940K
(10.86%↑ Y/Y)
Accounts payable
-$1,794K
(-197.18%↓ Y/Y)
Operating lease
liabilities
-$928K
(42.72%↑ Y/Y)
Long-term liabilities
-$388K
Back
Back
Cash Flow
Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics, Inc. (MAZE)
source: myfinsight.com